How is PT-141 dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds PT-141 (Bremelanotide) and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
PT-141 is bremelanotide1, and its US label, Vyleesi, gives one dose for premenopausal women with acquired, generalized hypoactive sexual desire disorder: 1.75 mg injected subcutaneously as needed at least 45 minutes before anticipated sexual activity.2
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 5 mg | 5 mg/mL: 750 mcg is 15 units, 1,250 mcg is 25 units, 1,750 mcg is 35 units | 2.5 mg/mL: 750 mcg is 30 units, 1,250 mcg is 50 units, 1,750 mcg is 70 units |
| 10 mg | 10 mg/mL: 750 mcg is 7.5 units, 1,250 mcg is 12.5 units, 1,750 mcg is 17.5 units | 5 mg/mL: 750 mcg is 15 units, 1,250 mcg is 25 units, 1,750 mcg is 35 units |
Mixing PT-141 powder: vial, water and syringe units
A DailyMed search found one bremelanotide label, Vyleesi3, and it is a ready-made solution of 1.75 mg in 0.3 mL in a single-dose autoinjector, not a powder.2 No label, regulator or maker's leaflet in the evidence gives a vial strength, a water type or mixing steps for PT-141 powder, so the vial table above is arithmetic only. The table's doses, 750, 1250 and 1750 mcg, are the three bremelanotide arms of the phase 2b trial of 397 women (Clayton, 2016)45, whose authors found 0.75 mg did not differ from placebo, and the label's 1.75 mg dose.2 For the general steps, see the mixing guide; the PT-141 calculator covers other vials and water volumes.
1,750 mcg of PT-141 (Bremelanotide) from a 10 mg vial mixed with 2 mL is 35 units on a U-100 syringe.
As arithmetic only, 1750 mcg, the label's 1.75 mg dose, from a 10 mg vial mixed with 2 mL is 5 mg per mL and 0.35 mL, which is 35 units on a U-100 syringe; the label's own autoinjector holds 1.75 mg in 0.3 mL.2
What the label says about dose and schedule
The label's dose is for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance, and the label states it is not indicated in postmenopausal women or in men.2 The label's two identical, 24-week, placebo-controlled phase 3 trials had 1247 premenopausal women with acquired, generalized HSDD2; the RECONNECT report (Kingsberg, 2019) gives 1,267 randomized and 1,247 in the safety population.6 The label gives one fixed dose with no titration steps; it says the duration of efficacy after each dose is unknown, the optimal window has not been fully characterized, and patients may decide the optimal time based on how they experience the duration of effect on desire and any adverse reactions such as nausea.2 The label's figure, more than 8 doses a month not recommended2, is lower than the phase 3 trials' limit of twelve doses a month2 and the up to 30 doses a month supplied in the extension that 684 women entered (Simon, 2019).7
Dose and schedule in each trial
In the phase 2b dose-finding trial (Clayton, 2016)5 of 397 premenopausal women with HSDD, FSAD or both, the authors concluded that 1.25 and 1.75 mg were effective over 12 weeks and 0.75 mg did not differ from placebo.4 The two RECONNECT phase 3 trials (Kingsberg, 2019; 1,267 women randomized) then compared 1.75 mg as needed with placebo over 24 weeks, a dose "selected for phase 3 studies based on optimal efficacy and an acceptable safety profile".6
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Clayton 2016, phase 2b45 | 0.75, 1.25 or 1.75 mg or placebo, subcutaneous, as desired at home | 397 premenopausal women with FSAD, HSDD or both | 12 weeks |
| Kingsberg 2019, RECONNECT (two trials)6 | 1.75 mg or placebo, subcutaneous, as needed | 1,267 women randomized, premenopausal with HSDD | 24 weeks |
| Simon 2019, open-label extension7 | 1.75 mg subcutaneous as needed, no more than one dose within 24 hours; resupply of up to 30 doses a month | 684 of 856 eligible women enrolled; 272 completed | 52 weeks |
| Diamond 2006, women1 | A single 20 mg intranasal dose or placebo in one in-clinic session and the other in the second (crossover) | Eighteen premenopausal women with female sexual arousal disorder | Two in-clinic sessions |
| Diamond 2005, men8 | 7.5 mg intranasal PT-141 with 25 mg sildenafil, against 25 mg sildenafil with a placebo spray and a placebo tablet with a placebo spray (crossover) | Nineteen men with erectile dysfunction who were responders to Viagra or Levitra by self-report | Three crossover treatments, 6-hour postdose period |
How PT-141 is stored
The label gives storage for the Vyleesi autoinjector at or below 25°C (77°F), not frozen and protected from light.2 The autoinjector is thrown away after the single injection.2 The evidence searched holds no stability data for a mixed powder, so no storage time for a mixed vial is given here.
Frequently asked questions
Is there a PT-141 nasal spray?
The Vyleesi label covers a subcutaneous injection2; intranasal bremelanotide appears in early trials, such as 20 mg or placebo in a crossover trial of eighteen premenopausal women with female sexual arousal disorder (Diamond, 2006)1. No approved or labelled nasal spray, and no recommended nasal dose, is in the sources searched.
Is there a PT-141 dose for men?
References
- peer-reviewed journal. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. 2006. pubmed.ncbi.nlm.nih.gov
- Cosette Pharmaceuticals (DailyMed). These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019. 2026. dailymed.nlm.nih.gov
- DailyMed (US National Library of Medicine). DailyMed label search: bremelanotide. dailymed.nlm.nih.gov
- peer-reviewed journal. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. 2016. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT01382719: Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder. 2014. clinicaltrials.gov
- peer-reviewed journal. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. 2019. pmc.ncbi.nlm.nih.gov
- peer-reviewed journal. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. 2019. pmc.ncbi.nlm.nih.gov
- peer-reviewed journal. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. 2005. pubmed.ncbi.nlm.nih.gov